Lv41
460 积分 2021-01-23 加入
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
1小时前
已完结
A Primary Report 166 Cases of Abdominal or Pelvic Neuroblastoma Surgery Utilizing the International Neuroblastoma Surgical Report Form (INSRF)
6天前
已完结
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
9天前
已完结
The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma
9天前
已完结
Utility of Assessing Early Tumor Shrinkage as an Efficacy Predictor in Patients with Non-Surgically Indicated or Recurrent Esophageal Cancer Treated with Nivolumab plus Ipilimumab
9天前
已关闭
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer
9天前
已完结
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
9天前
已完结
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
21天前
已完结
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
21天前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
28天前
已完结
皖公网安备34019202002308
